Therapy-related B-lymphoblastic leukemia after multiple myeloma. (2022)

• Record Type: Journal Article
• Authors: Kallen, Michael E.; Koka, Rima; Singh, Zeba N.; Ning, Yi; Kocoglu, Mehmet H.; Badros, Ashraf Z.; Niyongere, Sandrine; Duong, Vu H.; Emadi, Ashkan; Baer, Maria R.
• Is Part Of: Leukemia research reports. Volume 18(2022)
• Publication Date: 2022
• Subjects: Therapy-related B-lymphoblastic leukemia (t-B-ALL) -- Multiple myeloma (MM) -- Lenalidomide -- Melphalan; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2022.100358
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: New therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for multiple myeloma, which included lenalidomide maintenance. A subset of patients had pancytopenia and low-level marrow involvement by acute leukemia, an unusual finding in de novo B-ALL. One patient died of chemotherapy complications; the other seven responded. No patient died of B-ALL (median follow up of 1.0 years). Our series suggests that t-B-ALL is clonally unrelated to myeloma, presents with diverse cytogenetic abnormalities, and responds well to B-ALL therapy.